“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial looking at saracatinib in post menopausal women with advanced breast cancer (ARISTACAT)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at combining a new drug called saracatinib with hormone therapy for post menopausal women with advanced breast cancer.
Sometimes the aromatase inhibitor stops working and the cancer starts to grow again.
In this trial doctors want to use a new drug called saracatinib, a type of biological therapy with an aromatase inhibitor. They want to find out if together they can help to control the cancer for longer.
The aims of this trial are to find out
- If saracatinib and an aromatase inhibitor together are better than an aromatase inhibitor alone at delaying the growth of breast cancer
- About the side effects
Who can enter
You may be able to enter this trial if you
post menopausaland have advanced breast cancer that is ER positive
- Have cancer that can easily be measured by CT scan
- Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
- Have breast cancer and your doctors plan to treat you with an aromatase inhibitor
- Have cancer that is HER2 negative, or your cancer is HER2 positive and you are unable to have anti HER2 treatment – your doctor will explain this
- Are likely to benefit from treatment with an aromatase inhibitor - your doctor will discuss this with you
- Have satisfactory blood test results
- Are at least 18 years old
You cannot enter this trial if you
- Have any medical condition that would make it unsafe for you to take part in this trial
- Have had more than 2 courses of aromatase inhibitors in the past
- Have cancer that is getting worse in your lungs, liver or central nervous system (
- Have certain problems with your heart
- Are unable to take saracatinib (AZD0530) or aromatase inhibitors
- Are having chemotherapy or anti-HER2 therapy
- Are pregnant or breastfeeding
This trial will recruit 140 women from the UK.
This is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
The other half have an aromatase inhibitor (anastrozole or exemestane) and a dummy drug (
Anastrozole, exemestane, saracatinib and placebo are all tablets you take daily. You continue to have the trial treatment for as long as it is helping you and you are happy to continue.
If you agree to take part in this trial, the researchers will ask for a sample of tissue taken when you had surgery to remove your cancer. If this is not available they will ask to take a tissue sample (
You see the doctors and have some tests before you start treatment. The tests include
- Physical examination
- Dental check up (with your dentist if needed)
- Blood tests
- Urine tests
- CT scan
- MRI scan
- Heart trace (
- Optional tissue sample (
You see the doctors and have blood and urine tests more often than usual while you are taking the trial medication.
You have a CT scan or MRI scan
- Every 3 months for 18 months
- Then every 6 months
You see the doctors again when you stop taking the medication and have blood and urine tests.
The doctors now see you or ring you up every 3 months to see how you are.
As saracatinib is a new drug there may be side effects the doctors don’t know about yet. Possible side effects include
- Feeling or being sick
- Muscle weakness
- Flu like symptoms
- A drop in white blood cells causing an increased risk of infection
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Cameron
Cancer Research UK
Common Services Agency
Experimental Cancer Medicine Centre (ECMC)
ISD Cancer Clinical Trials Team
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/11/023.